Europeans are Interested in Online Patient Education Programs

Manhattan ResearchHalf of Europeans using the Internet for health information are interested in online patient education programs from pharmaceutical companies, although just a small fraction are currently using these types of programs, according to Manhattan Research's Cybercitizen Health® Europe v10.0 research. The survey explored the digital media and online health behaviors of 3,000 online adults in France, Germany, Italy, Spain, and the United Kingdom.

This strong demand in online patient education programs represents an opportunity for pharmaceutical companies, especially given the strong limits on direct consumer advertising. Additionally, the population of consumers in France, Germany, Italy, Spain, and the United Kingdom using the Internet for pharmaceutical information has increased considerably in recent years, growing from 54.7 million consumers in 2008 to 75 million consumers in 2010.

Highlights from the Study:

  • 89% of online European adults (154 million) use the Internet for health info in 2010.
  • 44% of online European adults use the Internet for pharmaceutical information.
  • Wikipedia is either the #1 or #2 website used for health information in the UK, Spain, Italy, France, and Germany.
  • Half of Europeans using the Internet for health information are interested in online patient education programs from pharmaceutical companies.

Key Questions Answered in Cybercitizen Health® Europe v10.0:

Mobile Device Adoption

  • Which kinds of mobile devices do consumers own and plan to purchase (including iPad, iPod Touch and various smartphone brands)?
  • How strong is adoption of apps on mobile devices vs. browser use, and which genres of apps garner the highest adoption?
  • Which barriers are limiting more advanced use of mobile device features?
  • How fast is use of mobile devices for health growing?
  • How interested are consumers in using pharma-sponsored mobile health apps?

Health Information Seeking Behavior

  • How strong is demand for prescription drug information online?
  • How localized is health information seeking behavior (U.S. vs. national)?
  • To what extent do consumers use U.S. based prescription drug websites?
  • How strong is adoption of pharma-sponsored condition websites?
  • What are consumer behaviors when selecting health-related search engine results?
  • To what degree does trust vs. relevance drive search engine result choices?

Social Media

  • To what degree do consumers alter their treatment decisions as a result of health related social media?
  • What need is health social media filling for European consumers?

E-Empowered European Consumers

  • What evidence is there that online health resources are impacting European consumers' health decisions or actions?
  • To what degree do European consumers believe online health resources are improving?

About Cybercitizen Health® Europe v10.0
Cybercitizen Health® Europe v10.0 was fielded online in Q3 2010 among 3,000 adults (age 18+) in France, Germany, Italy, Spain, and the United Kingdom.

For more information, please visit http://www.manhattanresearch.com/ccheu.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm and conducts annual research studies covering eHealth trends among healthcare professionals and consumers. For more information, please visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresources.com.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...